key: cord-0815541-cwm3y0vq authors: Ozturk, Ali; Bozok, Taylan; Simsek Bozok, Tugce title: Evaluation of rapid antibody test and chest computed tomography results of COVID‐19 patients: A retrospective study date: 2021-08-06 journal: J Med Virol DOI: 10.1002/jmv.27209 sha: 76d3afe21f80b13f4aaf475a53ba2f8b40b391e3 doc_id: 815541 cord_uid: cwm3y0vq The purpose of this study was to evaluate the SARS‐CoV‐2 immunoglobulin M/immunoglobulin G (IgM/IgG) rapid antibody test results in symptomatic patients with COVID‐19 and their chest computed tomography (CT) data. A total of 320 patients admitted to our hospital for different durations due to COVID‐19 were included in the study. Serum samples were obtained within 0–7 days from COVID‐19 patients confirmed by reverse‐transcription polymerase chain reaction (RT‐PCR) and chest CT scan. According to the SARS‐CoV‐2 RT‐PCR results, the patients included in the study were divided into two groups: PCR positive group (n = 46) and PCR negative group (n = 274). The relationship between chest CT and rapid antibody test results were compared statistically. Of the 320 COVID‐19 serum samples, IgM, IgG, and IgM/IgG were detected in 8.4%, 0.3%, and 11.6% within 1 week, respectively. IgG/IgM antibodies were not detected in 79.7% of the patients. In the study, 249 (77.8%) of 320 patients had positive chest CT scans. Four (5.6%) of 71 patients with negative chest CT scans had IgM and two (2.8%) were both IgM/IgG positive. IgM was detected in 23 (9.2%), IgG in one (0.4%), and IgM/IgG in 35 (14%) of chest CT scan positive patients. The rate of CT findings in patients with antibody positivity was found to be significantly higher than those with antibody negativity. The results of the present study show the accurate and equivalent performance of serological antibody assays and chest CT in detecting SARS‐CoV‐2 within 0–7 days from the onset of COVID19 symptoms. When RT‐PCR is not available, we believe that the combination of immunochromatographic test and chest CT scan can increase diagnostic sensitivity for COVID‐19. requires special equipment and trained laboratory technicians, it is not widely used in the clinical setting. As the RT-PCR test is performed on the upper and lower respiratory tract samples, it increases the risk of exposure to viral droplets during the collection and RNA isolation process. Therefore, alternative diagnostic tests to RT-PCR are required for the clinical management of COVID-19. Detection of antibodies against SARS-CoV-2 can play a complementary role with the RT-PCR test in the diagnosis of COVID-19 and in evaluating the immune status of individuals. Also, serological data will enable the gathering of important epidemiological information about the spread of the epidemic, and its morbidity and mortality. Additionally, the detection of antibodies against SARS-CoV-2 will play an important role in determining vaccine development strategies. 1, 3, 4 As a routine imaging tool in the diagnosis of COVID-19, chest computed tomography (CT) scan is a relatively easy, fast, and noninvasive radiological diagnostic tool. Chest CT analysis plays an important role not only in early detection and diagnosis especially in false-negative RT-PCR tests but also in monitoring the clinical course and evaluating the severity of the disease. 5, 6 It has been reported that the RT-PCR test is only 30%-60% sensitive in the diagnosis of COVID-19, and is less sensitive than chest CT during the early course of the disease. For example, five suspected cases were shown to have ground-glass opacity and/or mixed consolidation on chest CT scan, but the initial RT-PCR test was negative. A few days later, all five cases tested for the second or third examinations were confirmed as positive for SARS-CoV-2. 6, 7 In cases where the RT-PCR test of symptomatic and/or asymptomatic cases is negative, serological tests and chest CT scanning can be considered complementary tests for the RT-PCR technique. It may also be useful in the diagnosis of SARS-Cov-2 infection by providing promising clinical findings. Findings to be obtained from antibody testing will bring benefits for epidemiological studies for the COVID-19 pandemic in Nigde, Turkey. Thus, it will provide advantages such as increasing the reliability of test results and preventing epidemics. This study aimed to evaluate the SARS-CoV-2 immunoglobulin M/immunoglobulin G (IgM/IgG) rapid antibody test results from serum samples taken from admitted patients with suspected COVID-19 and their chest CT data. Blood samples taken from the patients (5-6 ml) were placed in tubes containing separator gel (SST) and centrifuged at 10,000g for 5 min. Patient sera were stored at −80°C until the day of the study. All risks related to the storage condition and transporting of the samples were applied following the conditions specified by the Turkish Republic Ministry of Health and Microbiology Laboratory guidelines. 8 SPSS 20.0 was used for statistical analysis. χ 2 test was used in statistical analysis. Pearson correlation test was used to see the level of agreement between the rapid antibodies test and chest CT scan. Significance was set at a p < 0.05. Cohen's κ statistics were used to evaluate the correlation between rapid antibody testing and chest CT methods. In this retrospective study, a total of 320 patients including 162 (50.6%) male and 158 (49.4%) female were included. The patients were between the ages of 18-90 (mean age 54.14). The clinical signs of COVID-19 patients are shown in Table 1 . The most common symptoms in patients were; fever (75.3%), headache (70.6%), myalgia (67.5%), cough (67.8%), dyspnea (25%), loss of taste and smell (19.7%), and diarrhea (4.0%). RT-PCR results of 320 patients were determined as 46 (13.2%) positive and 274 (85.6%) negative. In the negative control patient group (n = 40), only two serum samples were found IgG positive. We think it is likely due to the imperfect performance of existing tests and cross-reaction with seasonal CoVs. When the rapid antibody test and chest CT scan results were evaluated together ( Cohen's κ coefficient test was adopted for the analysis in the study. The Cohen's κ coefficient value was 0.08 (95% confidence interval, 0.024-0.13, p = 0.005), which represented the slight agreement between the two diagnostic methods. The positive predictive value and negative predictive value of rapid antibody test and chest CT findings were 23.69%, and 91.55%, respectively. evaluate COVID-19, especially during the epidemic period. 15 Studies have shown that the sensitivity of chest CT in symptomatic patients is high (74.3%-97%). The clinical performance of chest CT depends on factors such as patient population differences, disease severity, and accessibility to chest CT scans. [16] [17] [18] In this study, the antibody response in symptomatic COVID-19 patients was investigated with the rapid IgM/IgG card test. The serological data obtained were evaluated with the chest CT scan data of the same patients. The rapid antibody test used in this study was found to be less sensitive (20.3%, 65/320) for serum samples collected within 0-7 days from the onset of symptoms. Test performance features (sensitivity 95.7% and specificity 97.3%) provided by the manufacturer were found higher than those observed in our study. In the present study, IgM/IgG antibodies were not detected in 255 (79.7%) of the patient samples. This is likely due to a variety of factors, such as the state of the patient's immune system, quality and type of specimen, sample collection time, antibody level, and sample processing techniques. In our study, the chest CT scan was positive in 249 of the symptomatic patients. The chest CT scans were found to be positive in 90.8% of the patients who were antibody positive and 74.5% in those who were antibody negative (Table 3) . A study evaluating rapid antibody test and chest CT scan method was performed by Imai et al. 12 When the data obtained in our study were examined, the sensitivity of rapid antibody tests alone was not found to be sufficient in the diagnosis of COVID-19 within 1 week from the onset of COVID-19 symptoms. This study shows the accurate and equivalent performance of serological antibody assays and chest CT in diagnosing COVID-19 within 0-7 days from the onset of COVID19 symptoms. Therefore, to properly manage the pandemic process, we believe that the combination of immunochromatographic test and chest CT scan can serve as a rapid diagnostic test of RT-PCR-negative suspected patients and screening of SARS CoV-2 carriers. These tests/methods cannot take the place of RT-PCR but may increase the diagnostic sensitivity for COVID-19. The authors declare that there are no conflicts of interest. This study was reviewed and approved by the Ethics Committee of Nigde Omer Halisdemir University Faculty of Medicine (Approval no. 2020/21). Ali Ozturk designed the study. Ali Ozturk and Taylan Bozok conducted the laboratory tests. Ali Ozturk, Taylan Bozok and Tugce Simsek Bozok collected and analyzed the data. Ali Ozturk prepared the manuscript. Ali Ozturk, Taylan Bozok and Tugce Simsek Bozok edited and reviewed the manuscript. All the authors critically reviewed and revised the manuscript draft, and approved the final version of the manuscript. Ali Ozturk http://orcid.org/0000-0003-2428-1831 Taylan Bozok http://orcid.org/0000-0002-7094-4838 Tugce Simsek Bozok http://orcid.org/0000-0002-6611-978X A sensitive and specific antigen detection assay for Middle East respiratory syndrome coronavirus A serological assay to detect SARS-CoV-2 seroconversion in humans Antibody detection and dynamic characteristics in patients with coronavirus disease 2019 Antibody responses to sars-cov-2 in patients with novel coronavirus disease 2019 Antibody responses to SARS-CoV-2 in patients with COVID-19 Characteristics of patients with coronavirus disease (COVID-19) confirmed using an IgM-IgG antibody test Characterization of anti-MERS-CoV antibodies against various recombinant structural antigens of MERS-CoV in an importedcase in China Republic of Turkey Ministry of Health. COVID-19 (SARS-CoV2 infection) guide. 2020. 1-31 Antibody detection and dynamic characteristics in patients with coronavirus disease 2019 In vitro diagnostic assays for COVID-19: recent advances and emerging trends Rapid SARS-CoV-2 antigen detection assay in comparison with real-time RT-PCR assay for laboratory diagnosis of COVID-19 in Thailand Clinical evaluation of an immunochromatographic IgM/IgG antibody assay and chest computed tomography for the diagnosis of COVID-19 Clinical, molecular, and epidemiological characterization of the SARS-CoV-2 virus and the coronavirus disease 2019 (COVID-19), a comprehensive literature review Comparison of diagnostic accuracies of rapid serological tests and ELISA to molecular diagnostics in patients with suspected coronavirus disease 2019 presenting to the hospital Radiological changes observed in COVID 19 pneumonia and utilization of CT scan as a screening tool along with a real-time reverse transcriptase-polymerase chain reaction (rRT-PCR) for effective diagnosis Computed tomography and patient risk: facts, perceptions and uncertainties Review of the chest CT differential diagnosis of ground-glass opacities in the COVID era Correlation of chest ct and RT-PCR testing for coronavirus disease 2019 (COVID-19) in China: a report of 1014 cases How to cite this article: Ozturk A, Bozok T, Simsek Bozok T. Evaluation of rapid antibody test and chest computed tomography results of COVID-19 patients: A retrospective study